Frontiers in Oncology (Jun 2023)

Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy

  • Jiarna R. Zerella,
  • Jiarna R. Zerella,
  • Claire C. Homan,
  • Claire C. Homan,
  • Peer Arts,
  • Peer Arts,
  • Anna L. Brown,
  • Anna L. Brown,
  • Anna L. Brown,
  • Hamish S. Scott,
  • Hamish S. Scott,
  • Hamish S. Scott,
  • Christopher N. Hahn,
  • Christopher N. Hahn,
  • Christopher N. Hahn

DOI
https://doi.org/10.3389/fonc.2023.1183318
Journal volume & issue
Vol. 13

Abstract

Read online

Transcription factors (TFs) play a critical role as key mediators of a multitude of developmental pathways, with highly regulated and tightly organized networks crucial for determining both the timing and pattern of tissue development. TFs can act as master regulators of both primitive and definitive hematopoiesis, tightly controlling the behavior of hematopoietic stem and progenitor cells (HSPCs). These networks control the functional regulation of HSPCs including self-renewal, proliferation, and differentiation dynamics, which are essential to normal hematopoiesis. Defining the key players and dynamics of these hematopoietic transcriptional networks is essential to understanding both normal hematopoiesis and how genetic aberrations in TFs and their networks can predispose to hematopoietic disease including bone marrow failure (BMF) and hematological malignancy (HM). Despite their multifaceted and complex involvement in hematological development, advances in genetic screening along with elegant multi-omics and model system studies are shedding light on how hematopoietic TFs interact and network to achieve normal cell fates and their role in disease etiology. This review focuses on TFs which predispose to BMF and HM, identifies potential novel candidate predisposing TF genes, and examines putative biological mechanisms leading to these phenotypes. A better understanding of the genetics and molecular biology of hematopoietic TFs, as well as identifying novel genes and genetic variants predisposing to BMF and HM, will accelerate the development of preventative strategies, improve clinical management and counseling, and help define targeted treatments for these diseases.

Keywords